A PHASE II STUDY OF SUTENT SUNITINIB, AN ORAL MULTITARGETED TYROSINE KINASE INHIBITOR IN SUBJECTS WITH NF-1 PLEXIFORM NEUROFIBROMAS
$1,308,192FY2011Department of DefenseDOD
Trustees Of Indiana University, Bloomington IN
Trustees Of Indiana University, Bloomington IN